Pfizer registers Phase 3 marstacimab hemophilia trial and elranatamab myeloma comparison studyNov 12Weekly roundup, 10 itemsabrocitinibberobenatide
FDA grants accelerated approval to elranatamab-bcmm for multiple myelomaNov 10Regulatory decisionelranatamab-bcmm
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
C4 Therapeutics presents cemsidomide biomarker data at IMS Annual MeetingSep 25Clinical readoutC4 Therapeutics, Inc.cemsidomide
C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 dataAug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide